Post-earnings recap
Reported
Tue, May 7, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a strong EPS performance, beating expectations significantly. However, the stock reacted negatively, dropping 1.04%. The lack of revenue data and forward guidance may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.26 | N/A | +29.88% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide any forward guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—